• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

American Pacific Reports Fiscal 2009 Third Quarter Results - Reaffirms Fiscal Earnings 2009 Guidance

Posted on: Tuesday, 4 August 2009, 15:02 CDT

LAS VEGAS, Aug. 4 /PRNewswire-FirstCall/ -- American Pacific Corporation (Nasdaq: APFC) today reported financial results for its fiscal 2009 third quarter ended June 30, 2009.

We provide non-GAAP measures as a supplement to financial results based on GAAP. A reconciliation of the non-GAAP measures to the most directly comparable GAAP measures is included in the accompanying supplemental data.

FINANCIAL SUMMARY

Quarter Ended June 30, 2009 Compared to Quarter Ended June 30, 2008

• Revenues decreased $5.2 million, or 14%, to $31.5 million from $36.7 million.
• Operating loss was $3.7 million compared to operating income of $2.4 million.
• Adjusted EBITDA was $0.6 million compared to $6.6 million.
• Net loss was $3.6 million compared to net income of $0.1 million.
• Diluted loss per share was ($0.48) compared to diluted earnings per share of $0.02.
  

Nine Months Ended June 30, 2009 Compared to Nine Months Ended June 30, 2008

• Revenues increased $1.6 million, or 1%, to $133.6 million from $132.0 million.
• Operating income decreased to $6.0 million from $15.0 million.
• Adjusted EBITDA decreased to $18.5 million from $28.7 million.
• Net loss was $1.4 million compared to net income of $4.6 million.
• Diluted loss per share was ($0.18) compared to diluted earnings per share of $0.61.
  

The condensed consolidated financial statements herein include the results of our recent acquisition of Marotta Holdings Limited (subsequently renamed Ampac ISP Holdings Limited), effective on October 1, 2008.

CONSOLIDATED RESULTS OF OPERATIONS

Revenues - For our fiscal 2009 third quarter, revenues decreased 14% to $31.5 million, reflecting an increase of 169% in Aerospace Equipment segment revenues, offset by decreases of 47% and 20% in Specialty Chemicals and Fine Chemicals revenues, respectively. For the nine months ended June 30, 2009, revenues increased 1% to $133.6 million, reflecting a 2% and 94% increase in Specialty Chemicals segment and Aerospace Equipment segment revenues, offset by a 12% decline in Fine Chemicals segment revenues.

See further discussion under Segment Highlights.

Cost of Revenues and Gross Margins - For our fiscal 2009 third quarter, cost of revenues was $24.2 million compared to $24.0 million for the prior fiscal year third quarter. The consolidated gross margin percentage was 23% and 35% for our fiscal 2009 and fiscal 2008 third quarters, respectively. For the nine months ended June 30, 2009, cost of revenues was $94.3 million compared to $85.2 million for the prior fiscal year nine-month period. The consolidated gross margin percentage was 29% and 35% for our fiscal 2009 and fiscal 2008 nine-month periods, respectively.

One of the most significant factors that affects, and should continue to affect, the comparison of our consolidated gross margins from period to period is the change in revenue mix between our segments. The revenue contribution by each of our segments is indicated in the following table.

Three Months Ended Nine Months Ended June 30, June 30, 2009 2008 2009 2008 ---- ---- ---- ---- Fine Chemicals 50% 53% 51% 58% Specialty Chemicals 20% 33% 31% 31% Aerospace Equipment 29% 9% 16% 9% Other Businesses 1% 5% 2% 2% - - - - Total Revenues 100% 100% 100% 100% === === === ===

In addition, consolidated gross margins for our fiscal 2009 periods reflect:

• Consistent gross margins for our Specialty Chemicals and Aerospace Equipment segments for the fiscal 2009 nine-month period compared to the prior year nine-month period.
• A decrease in Fine Chemicals segment gross margin percentage primarily due to manufacturing inefficiencies and volume declines.
  

See further discussion under Segment Highlights.

Operating Expenses - For our fiscal 2009 third quarter, operating expenses increased $0.5 million to $10.9 million from $10.4 million for the third quarter of the prior fiscal year primarily as a result of:

• A $0.4 million decrease in Fine Chemicals segment incentive compensation, as a result of recording no incentive compensation in fiscal 2009.
• An increase in Aerospace Equipment segment operating expenses primarily due to additional operating expenses of $0.7 million from the acquisition of AMPAC ISP Holdings.
• A decrease in corporate expenses, primarily due to a decrease of $0.3 million in incentive compensation, as a result of recording no incentive compensation in fiscal 2009.
• Other increases of $0.5 million.
  

For the nine months ended June 30, 2009, operating expenses increased $1.5 million to $33.3 million from $31.8 million for the nine months ended June 30, 2008 as a result of:

• A $1.2 million decrease in Fine Chemicals segment incentive compensation, as a result of recording no incentive compensation in fiscal 2009.
• A $0.8 million increase in Specialty Chemicals operating expenses primarily due to increases in employee benefit costs.
• An increase in Aerospace Equipment segment operating expenses primarily due to additional operating expenses in the amount of $1.7 million from the acquisition of AMPAC ISP Holdings.
• Consistent corporate expenses, primarily including increases in rent of $0.5 million, and increases in stock-based compensation of $0.4 million, offset by a decrease of $1.0 million in incentive compensation, as a result of recording no incentive compensation in fiscal 2009.
• Other increases of $0.3 million.
  

SEGMENT HIGHLIGHTS

Fine Chemicals Segment

Our Fine Chemicals segment reflects the operating results of our wholly-owned subsidiary Ampac Fine Chemicals LLC ("AFC").

Quarter Ended June 30, 2009 Compared to Quarter Ended June 30, 2008

• Revenues were $15.6 million compared to revenues( )of $19.7 million.
• Operating loss of $0.8 million compared to operating income of $0.6 million.
• Segment EBITDA was $2.5 million, or 16% of segment revenues, compared to Segment EBITDA of $3.7 million, or 19% of segment revenues.
  

Nine Months Ended June 30, 2009 Compared to Nine Months Ended June 30, 2008

• Revenues were $67.8 million compared to revenues( )of $76.9 million.
• Operating loss of $0.4 million compared to operating income of $9.4 million.
• Segment EBITDA was $9.3 million, or 14% of segment revenues, compared to Segment EBITDA of $18.9 million, or 25% of segment revenues.
  

The decrease in Fine Chemicals segment revenues for the fiscal 2009 third quarter compared to the prior fiscal year third quarter is primarily due to a decrease in revenues from central nervous system products. The decrease results from a customer reducing its orders for the product until calendar year 2010.

For the nine months ended June 30, 2009, the decrease in Fine Chemicals segment revenues, compared to the prior fiscal year nine-month period, primarily reflects a decline in revenues from oncology products of 22% due to timing between the interim periods, and a decline in revenues from central nervous system products of 41% related to the aforementioned production deferral.

Our Fine Chemicals segment reported an operating loss of $0.8 million for the fiscal 2009 third quarter and $0.4 million for the nine months ended June 30, 2009, each representing a significant decline over the prior year periods. The decrease in operating income reflects:

• A decrease in the gross margin percentage of approximately six points for the fiscal 2009 third quarter due to lower production volume and the related impact on gross margin due to less absorption of fixed manufacturing costs.
• A decrease in gross margin percentage of approximately thirteen points for the nine months ended June 30, 2009. In addition to the factor that contributed to the gross margin decline in the fiscal 2009 third quarter, the fiscal 2009 year-to-date decline in gross margin percentage includes:
  • During the fourth quarter of fiscal 2008, we implemented a new process for a large-volume anti-viral product and experienced start-up difficulties that negatively impacted margins for this product for the first half of fiscal 2009. These factors, combined with price reductions, account for approximately eight points in the gross margin decline for the fiscal 2009 nine-month period.
  • A decrease in revenues for central nervous system products, including a price reduction for a large-volume product, account for approximately two points in the gross margin decline.
  • The remaining decline is attributed primarily to product mix.
• A decrease in incentive compensation, classified as operating expenses, of $0.4 million for the fiscal 2009 third quarter and $1.2 million for the nine months ended June 30, 2009, each as compared to the prior year periods.
  

Specialty Chemicals Segment

Our Specialty Chemicals segment revenues include the operating results from our perchlorate, sodium azide and Halotron product lines, with perchlorates comprising 89% and 91% of Specialty Chemicals revenues in the fiscal 2009 and fiscal 2008 nine-month periods, respectively.

Quarter Ended June 30, 2009 Compared to Quarter Ended June 30, 2008

• Revenues decreased to $6.3 million from $11.9 million.
• Operating income was $0.6 million, or 9% of segment revenues, compared to $6.0 million, or 50% of segment revenues.
• Segment EBITDA was $0.9 million, or 14% of segment revenues, compared to $6.3 million, or 53% of segment revenues.
  

Nine Months Ended June 30, 2009 Compared to Nine Months Ended June 30, 2008

• Revenues increased to $40.9 million from $40.3 million.
• Operating income was $16.5 million, or 40% of segment revenues, compared to $16.8 million, or 42% of segment revenues.
• Segment EBITDA was $17.4 million, or 43% of segment revenues, compared to $19.2 million, or 48% of segment revenues.
  

The variances in Specialty Chemicals revenues reflect the following factors:

• A 75% decrease in perchlorate volume and a 70% increase in the related average price per pound for the fiscal 2009 third quarter.
• A 25% decrease in perchlorate volume and a 32% increase in the related average price per pound for the nine months ended June 30, 2009.
• Sodium azide revenues increased $1.3 million for the nine-month period ended June 30, 2009.
• Halotron revenues decreased $0.5 million for the nine-month period ended June 30, 2009.
  

The decreases in perchlorate volume for the fiscal 2009 third quarter and nine-month period reflect the timing of Grade I ammonium perchlorate ("AP") orders among the fiscal 2009 quarterly periods. The average price per pound increased for the fiscal 2009 third quarter and nine-month period because we sold more specialized blend product than in the comparable prior fiscal year periods.

For the fiscal 2009 nine-month period, the greatest contribution to segment revenue was product for the Space Shuttle Reusable Solid Rocket Motor ("RSRM") program. We currently expect annual demand for Grade I AP in fiscal 2009 to be consistent with fiscal 2008, and as a result, our fiscal 2009 fourth quarter is anticipated to reflect a significant volume and revenue increase over our fiscal 2009 third quarter. Increases in demand in fiscal 2009 for the Space Shuttle RSRM program, the Atlas V Solid Rocket Booster ("SRB") program and the Guided Multiple Launch Rocket System ("MLRS") program should offset declines from the completion in fiscal 2008 of the three-year Minuteman III propulsion replacement program.

Specialty Chemicals operating income was 9% of segment revenues, for the fiscal 2009 third quarter compared to 50% of segment revenues for the fiscal 2008 third quarter. This decrease is primarily due to lower perchlorate volume in the fiscal 2009 third quarter which affects operating margins in two ways. For the fiscal 2009 third quarter, perchlorates comprised 72% of Specialty Chemicals segment revenues compared to 89% in the prior year third quarter. The change in product mix to lower-margin azide and Halotron products was the primary contributor to a twenty-two point reduction in Specialty Chemicals segment gross margins. The remaining decline in operating income as a percentage of segment revenues is primarily attributed to the effect of having relatively fixed general and administrative expenses with lower gross profit than the prior year period.

For the fiscal 2009 nine-month period, Specialty Chemicals segment operating income was 40% of revenues compared to 42% for the prior year nine-month period. Gross margin as a percentage of revenues was consistent between the nine-month periods. Operating expenses increased $0.8 million primarily due to increases in employee benefit costs.

Aerospace Equipment Segment

Our Aerospace Equipment segment reflects the operating results of our wholly-owned subsidiary Ampac-ISP Corp. ("ISP") and its wholly-owned subsidiaries.

Effective October 1, 2008, we completed the acquisition of Marotta Holdings Limited (subsequently renamed Ampac ISP Holdings Limited) and its wholly-owned subsidiaries (collectively "AMPAC ISP Holdings"). Combined with our existing Aerospace Equipment operations in Westcott, U.K., these operations constitute AMPAC ISP Europe.

Quarter Ended June 30, 2009 Compared to Quarter Ended June 30, 2008

• Revenues increased 169% to $9.1 million from $3.4 million.
• Operating income was $0.4 million compared to an operating loss of $0.3 million.
• Segment EBITDA was $0.8 million compared to ($0.3) million.
  

Nine Months Ended June 30, 2009 Compared to Nine Months Ended June 30, 2008

• Revenues increased 94% to $22.0 million from $11.4 million.
• Operating income was $1.6 million compared to $0.2 million.
• Segment EBITDA was $2.6 million, or 12% of segment revenues, compared to $0.4 million, or 4% of segment revenues.
  

For the nine months ended June 30, 2009, Aerospace Equipment segment revenues increased $10.6 million due to both organic growth and the AMPAC ISP Holdings acquisition. AMPAC ISP Holdings contributed $4.0 million in revenues. The remainder of the revenue increase is primarily attributed to this segment's U.S. operations which experienced success in the latter part of fiscal 2008 with new contract awards. This improvement in backlog resulted in revenue increases in the fiscal 2009 periods.

The improvement in operating income for each of the fiscal 2009 periods is largely a function of the higher revenue levels which contributed more gross margins to cover general and administrative expenses. General and administrative expenses have increased during the 2009 periods, but at a slower rate than the revenue growth.

AMPAC ISP Holdings contributed segment EBITDA of approximately $0.4 million for the fiscal 2009 nine-month period.

CAPITAL AND LIQUIDITY HIGHLIGHTS

Liquidity - As of June 30, 2009, we had cash balances of $25.0 million and no cash borrowings against our $20.0 million revolving credit line. In addition, we were in compliance with the various covenants contained in our credit agreements.

Operating Cash Flows - Operating activities provided cash of $11.3 million for our fiscal 2009 nine-month period compared to $21.1 million for the prior fiscal year nine-month period, resulting in a decrease of $9.8 million.

Significant components of the change in cash flow from operating activities include:

• A decrease in cash provided by Adjusted EBITDA of $10.2 million.
• An increase in cash used for working capital accounts of $6.0 million, excluding the effects of interest and income taxes.
• A decrease in cash taxes paid of $4.3 million.
• An increase in cash used for environmental remediation of $0.2 million.
• Other increases in cash provided by operating activities of $2.3 million.
  

The increase in cash used for working capital accounts is primarily due to an increase in working capital requirements to support the revenue growth of our Aerospace Equipment segment.

We consider these working capital changes to be routine and within the normal production cycle of our products. The production of certain fine chemical products requires a length of time that exceeds one quarter. Therefore, in any given quarter, accounts receivable, work-in-progress inventory or deferred revenues can increase or decrease significantly. We expect that our working capital may vary normally by as much as $10.0 million from quarter to quarter.

For fiscal 2009, the Company does not anticipate paying federal income taxes based on the anticipated reduction in income and the affects of timing difference in expense deductions. As a result, cash tax requirements are significantly reduced in fiscal 2009 compared to fiscal 2008.

Other increases in cash provided by operating activities primarily reflect the timing of contributions to our defined benefit pension plans.

Investing Cash Flows -

• Capital expenditures decreased by $3.7 million in the fiscal 2009 nine-month period as compared to prior fiscal year nine-month period.
• Cash used for acquisition of business reflects the purchase of AMPAC ISP Holdings for $7.1 million, net of cash acquired of $0.4 million.
  

OUTLOOK

We are reaffirming our most recent earnings guidance for fiscal 2009. We expect consolidated revenues for fiscal 2009 of at least $193.0 million and Adjusted EBITDA to range from $29 million to $32 million. We are anticipating our capital expenditures for fiscal 2009 to be approximately $10.0 million.

The low end of the range of our fiscal 2009 guidance for Adjusted EBITDA is computed by adding estimated amounts for depreciation and amortization of $16.0 million, interest expense of $10.8 million, share-based compensation expense of $0.7 million and income taxes of $0.5 million to estimated net income of $1.0 million.

INVESTOR TELECONFERENCE

We invite you to participate in a teleconference with our executive management covering our fiscal 2009 third quarter financial results. The investor teleconference will be held Tuesday August 4, 2009 at 1:30 p.m., Pacific Daylight Time. The teleconference will include a presentation by management followed by a question and answer session. The teleconference can be accessed by dialing (973) 582-2852 between 1:15 and 1:30 p.m., Pacific Daylight Time. Please reference conference ID# 21992691. As is our customary practice, a live webcast of the teleconference is being provided by Thomson Financial's First Call Events. A link to the webcast and the earnings release is available at our website at www.apfc.com, and will be available for replay until a few days before our next quarterly investor teleconference.

RISK FACTORS/FORWARD-LOOKING STATEMENTS

Statements contained in this earnings release that are not purely historical are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including without limitation the statement regarding one of the significant factors that will affect our consolidated gross margins in the future, the statement regarding expected consolidated revenues for fiscal 2009 and expected Adjusted EBITDA, the statement regarding anticipated capital expenditures, statements regarding our beliefs about future demand for, and related volume of and revenue from sales of, AP, in particular Grade I AP, statements regarding our working capital changes and future variations, statements regarding anticipated federal income tax payments and related cash tax requirements, and statements in the "Outlook" section of this earnings release. Words such as "anticipate", "expect", "should", "may", "can" and similar expressions are intended to identify forward-looking statements. The inclusion of forward-looking statements should not be regarded as a representation by the Company that any of its expectations will be achieved. Actual results may differ materially from future results or outcomes expressed or implied by forward-looking statements set forth in the release due to risks, uncertainties and other important factors inherent in the Company's business. Factors that might cause actual results to differ include, but are not limited to, the following:

• We depend on a limited number of customers for most of our sales in our Specialty Chemicals, Aerospace Equipment and Fine Chemicals segments and the loss of one or more of these customers could have a material adverse effect on our financial position, results of operations and cash flows.
• The inherent limitations of our fixed-price or similar contracts may impact our profitability.
• The numerous and often complex laws and regulations and regulatory oversight to which our operations and properties are subject, the cost of compliance, and the effect of any failure to comply could reduce our profitability and liquidity.
• A significant portion of our business depends on contracts with the government or its prime contractors and these contracts are impacted by governmental priorities and are subject to potential fluctuations in funding or early termination, including for convenience, any of which could have a material adverse effect on our operating results, financial condition or cash flows.
• We may be subject to potentially material costs and liabilities in connection with environmental liabilities.
• Although we have established an environmental reserve for remediation activities in Henderson, Nevada, given the many uncertainties involved in assessing environmental liabilities, our environmental-related risks may from time to time exceed any related reserves.
• For each of our Specialty Chemicals, Fine Chemicals and Aerospace Equipment segments, most production is conducted in a single facility and any significant disruption or delay at a particular facility could have a material adverse effect on our business, financial position and results of operations.
• The release or explosion of dangerous materials used in our business could disrupt our operations and cause us to incur additional costs and liability.
• Disruptions in the supply of key raw materials and difficulties in the supplier qualification process, as well as increases in prices of raw materials, could adversely impact our operations.
• Each of our Specialty Chemicals, Fine Chemicals and Aerospace Equipment segments may be unable to comply with customer specifications and manufacturing instructions or may experience delays or other problems with existing or new products, which could result in increased costs, losses of sales and potential breach of customer contracts.
• Successful commercialization of pharmaceutical products and product line extensions is very difficult and subject to many uncertainties. If a customer is not able to successfully commercialize its products for which AFC produces compounds or if a product is subsequently recalled, then the operating results of AFC may be negatively impacted.
• A strike or other work stoppage, or the inability to renew collective bargaining agreements on favorable terms, could have a material adverse effect on the cost structure and operational capabilities of AFC.
• The pharmaceutical fine chemicals industry is a capital-intensive industry and if AFC does not have sufficient financial resources to finance the necessary capital expenditures, its business and results of operations may be harmed.
• We may be subject to potential liability claims for our products or services that could affect our earnings and financial condition and harm our reputation.
• Technology innovations in the markets that we serve may create alternatives to our products and result in reduced sales.
• We are subject to strong competition in certain industries in which we participate and therefore may not be able to compete successfully.
• Due to the nature of our business, our sales levels may fluctuate causing our quarterly operating results to fluctuate.
• The inherent volatility of the chemical industry affects our capacity utilization and causes fluctuations in our results of operations.
• A loss of key personnel or highly skilled employees could disrupt our operations.
• We may continue to expand our operations in part through acquisitions, which could divert management's attention and expose us to unanticipated liabilities and costs. We may experience difficulties integrating the acquired operations, and we may incur costs relating to acquisitions that are never consummated.
• We have a substantial amount of debt, and the cost of servicing that debt could adversely affect our ability to take actions, our liquidity or our financial condition.
• If we are unable to generate sufficient cash flow to service our debt and fund our operating costs, our liquidity may be adversely affected.
• Significant changes in discount rates, rates of return on pension assets, mortality tables and other factors could affect our estimates of pension obligations, which in turn could affect future funding requirements and related costs and impact our future earnings.
• Our shareholder rights plan, Restated Certificate of Incorporation, as amended, and Amended and Restated By-laws discourage unsolicited takeover proposals and could prevent stockholders from realizing a premium on their common stock.
• Our proprietary and intellectual property rights may be violated, compromised, circumvented or invalidated, which could damage our operations.
  

Readers of this earnings release are referred to our Annual Report on Form 10-K for the year ended September 30, 2008, our Quarterly Reports on Form 10-Q for the quarters ended December 31, 2008 and March 31, 2009, and our other filings with the Securities and Exchange Commission for further discussion of these and other factors that could affect our future results. The forward-looking statements contained in this earnings release are made as of the date hereof and we assume no obligation to update for actual results or to update the reasons why actual results could differ materially from those projected in the forward-looking statements, except as required by law. In addition, the operating results for the quarter and nine-month period ended June 30, 2009 and cash flows for the nine-month period ended June 30, 2009 are not necessarily indicative of the results that will be achieved for future periods.

ABOUT AMERICAN PACIFIC CORPORATION

American Pacific Corporation (AMPAC) is a leading custom manufacturer of fine chemicals, specialty chemicals and propulsion products within its focused markets. We supply active pharmaceutical ingredients and advanced intermediates to the pharmaceutical industry. For the aerospace and defense industry we provide specialty chemicals used in solid rocket motors for space launch and military missiles. AMPAC also designs and manufactures liquid propulsion systems, valves and structures for space and missile defense applications. We produce clean agent chemicals for the fire protection industry, as well as electro-chemical equipment for the water treatment industry. Our products are designed to meet customer specifications and often must meet certain governmental and regulatory approvals. Additional information about us can be obtained by visiting our web site at www.apfc.com.

AMERICAN PACIFIC CORPORATION Consolidated Statements of Operations (Unaudited, Dollars in Thousands, Except per Share Amounts) Three Months Ended Nine Months Ended June 30, June 30, 2009 2008 2009 2008 ---- ---- ---- ---- Revenues $31,490 $36,740 $133,554 $131,977 Cost of Revenues 24,227 23,990 94,260 85,188 ------ ------ ------ ------ Gross Profit 7,263 12,750 39,294 46,789 Operating Expenses 10,915 10,377 33,295 31,824 ------ ------ ------ ------ Operating Income (Loss) (3,652) 2,373 5,999 14,965 Interest and Other Income, Net 28 575 70 1,221 Interest Expense 2,683 2,682 8,061 8,073 ----- ----- ----- ----- Income (Loss) before Income Tax (6,307) 266 (1,992) 8,113 Income Tax Expense (Benefit) (2,752) 138 (627) 3,489 ------ --- ---- ----- Net Income (Loss) $(3,555) $128 $(1,365) $4,624 ======= ==== ======= ====== Earnings (Loss) per Share: Basic $(0.48) $0.02 $(0.18) $0.62 Diluted $(0.48) $0.02 $(0.18) $0.61 Weighted Average Shares Outstanding: Basic 7,483,000 7,452,000 7,482,000 7,442,000 Diluted 7,483,000 7,607,000 7,482,000 7,594,000 AMERICAN PACIFIC CORPORATION Consolidated Balance Sheets (Unaudited, Dollars in Thousands, Except per Share Amounts) June 30, September 30, 2009 2008 ---- ---- ASSETS Current Assets: Cash and Cash Equivalents $24,968 $26,893 Accounts Receivable, Net 27,495 27,445 Inventories 44,242 40,357 Prepaid Expenses and Other Assets 1,639 3,392 Income Taxes Receivable 1,967 1,804 Deferred Income Taxes 6,697 6,859 ----- ----- Total Current Assets 107,008 106,750 Property, Plant and Equipment, Net 115,242 118,608 Intangible Assets, Net 4,106 3,013 Goodwill 3,152 - Deferred Income Taxes 14,026 13,849 Other Assets 10,292 9,193 ------ ----- TOTAL ASSETS $253,826 $251,413 ======== ======== LIABILITIES AND SHAREHOLDERS' EQUITY Current Liabilities: Accounts Payable $8,246 $10,554 Accrued Liabilities 4,703 5,526 Accrued Interest 4,125 1,650 Employee Related Liabilities 5,737 6,917 Income Taxes Payable 12 111 Deferred Revenues and Customer Deposits 8,283 3,091 Current Portion of Environmental Remediation Reserves 1,412 996 Current Portion of Long-Term Debt 213 254 --- --- Total Current Liabilities 32,731 29,099 Long-Term Debt 110,105 110,120 Environmental Remediation Reserves 11,879 13,282 Pension Obligations 16,551 15,692 Other Long-Term Liabilities 589 258 --- --- Total Liabilities 171,855 168,451 ------- ------- Commitments and Contingencies Shareholders' Equity Preferred Stock - $1.00 par value; 3,000,000 authorized; none outstanding - - Common Stock - $0.10 par value; 20,000,000 shares authorized, 9,550,541 and 9,523,541 issued 955 952 Capital in Excess of Par Value 88,999 88,496 Retained Earnings 14,591 15,956 Treasury Stock - 2,045,950 and 2,045,950 shares (17,175) (17,175) Accumulated Other Comprehensive Loss (5,399) (5,267) ------ ------ Total Shareholders' Equity 81,971 82,962 ------ ------ TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY $253,826 $251,413 ======== ======== AMERICAN PACIFIC CORPORATION Consolidated Statements of Cash Flow (Unaudited, Dollars in Thousands) Nine Months Ended June 30, 2009 2008 ---- ---- Cash Flows from Operating Activities: Net Income (Loss) $(1,365) $4,624 Adjustments to Reconcile Net Income (Loss) to Net Cash Provided by Operating Activities: Depreciation and amortization 11,971 12,472 Non-cash interest expense 473 478 Share-based compensation 474 90 Excess tax benefit from stock option exercises - (244) Deferred income taxes (14) (447) Loss (Gain) on sale of assets 52 (418) Changes in operating assets and liabilities: Accounts receivable, net 2,284 3,800 Inventories (4,847) (10,924) Prepaid expenses and other current assets 1,792 (1,766) Accounts payable (2,780) (1,312) Income taxes (262) 1,158 Accrued liabilities (1,034) (1,011) Accrued interest 2,475 2,438 Employee related liabilities (1,298) (384) Deferred revenues and customer deposits 3,567 15,488 Environmental remediation reserves (987) (757) Pension obligations, net 859 (199) Other (8) (1,945) -- ------ Net Cash Provided by Operating Activities 11,352 21,141 ------ ------ Cash Flows from Investing Activities: Capital expenditures (6,312) (10,027) Acquisition of business, net of cash acquired (6,725) - ------ - Net Cash Used by Investing Activities (13,037) (10,027) ------- ------- Cash Flows from Financing Activities: Payments of long-term debt (272) (208) Issuances of common stock, net 32 387 Excess tax benefit from stock option exercises - 244 Purchases of treasury stock - (193) - ---- Net Cash Provided (Used) by Financing Activities (240) 230 ---- --- Net Change in Cash and Cash Equivalents (1,925) 11,344 Cash and Cash Equivalents, Beginning of Period 26,893 21,426 ------ ------ Cash and Cash Equivalents, End of Period $24,968 $32,770 ======= ======= AMERICAN PACIFIC CORPORATION Supplemental Data (Unaudited, Dollars in Thousands) Three Months Ended Nine Months Ended June 30, June 30, 2009 2008 2009 2008 ---- ---- ---- ---- Operating Segment Data: Revenues: Fine Chemicals $15,644 $19,654 $67,766 $76,920 Specialty Chemicals 6,299 11,942 40,940 40,278 Aerospace Equipment 9,085 3,380 21,977 11,350 Other Businesses 462 1,764 2,871 3,429 --- ----- ----- ----- Total Revenues $31,490 $36,740 $133,554 $131,977 ======= ======= ======== ======== Segment Operating Income (Loss): Fine Chemicals $(752) $621 $(370) $9,426 Specialty Chemicals 552 5,998 16,481 16,768 Aerospace Equipment 417 (330) 1,571 248 Other Businesses (215) 341 164 340 ---- --- --- --- Total Segment Operating Income 2 6,630 17,846 26,782 Corporate Expenses (3,654) (4,257) (11,847) (11,817) ------ ------ ------- ------- Operating Income (Loss) $(3,652) $2,373 $5,999 $14,965 ======= ====== ====== ======= Depreciation and Amortization: Fine Chemicals $3,281 3,115 $9,625 9,505 Specialty Chemicals 324 302 951 2,392 Aerospace Equipment 378 60 1,032 156 Other Businesses 3 3 9 9 Corporate 115 155 354 410 --- --- --- --- Total Depreciation and Amortization $4,101 $3,635 $11,971 $12,472 ====== ====== ======= ======= Segment EBITDA (a): Fine Chemicals $2,529 $3,736 $9,255 $18,931 Specialty Chemicals 876 6,300 17,432 19,160 Aerospace Equipment 795 (270) 2,603 404 Other Businesses (212) 344 173 349 ---- --- --- --- Total Segment EBITDA 3,988 10,110 29,463 38,844 Less: Corporate Expenses, Excluding Depreciation (3,539) (4,102) (11,493) (11,407) Plus: Share-based Compensation 169 37 474 90 Plus: Interest and Other Income (Expense), Net 28 575 70 1,221 --- --- --- ----- Adjusted EBITDA (b) $646 $6,620 $18,514 $28,748 ==== ====== ======= ======= Reconciliation of Net Income (Loss) to Adjusted EBITDA (b): Net Income (Loss) $(3,555) $128 $(1,365) $4,624 Add Back: Income Tax Expense (Benefit) (2,752) 138 (627) 3,489 Interest Expense 2,683 2,682 8,061 8,073 Depreciation and Amortization 4,101 3,635 11,971 12,472 Share-based Compensation 169 37 474 90 --- --- --- --- Adjusted EBITDA $646 $6,620 $18,514 $28,748 ==== ====== ======= ======= (a) Segment EBITDA is defined as segment operating income (loss) plus depreciation and amortization. (b) Adjusted EBITDA is defined as net income (loss) before income tax expense (benefit), interest expense, depreciation and amortization, share-based compensation and environmental remediation charges (if any). Segment EBITDA and Adjusted EBITDA are not financial measures calculated in accordance with GAAP and should not be considered as an alternative to income (loss) from operations as performance measures. Each EBITDA measure is presented solely as a supplemental disclosure because management believes that each is a useful performance measure that is widely used within the industries in which we operate. In addition, EBITDA measures are significant measurements for covenant compliance under our revolving credit facility. Each EBITDA measure is not calculated in the same manner by all companies and, accordingly, may not be an appropriate measure for comparison.

SOURCE American Pacific Corporation

Source: PR Newswire

More News in this Category